{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:58:43Z","timestamp":1792785523177,"version":"4.5.0"},"reference-count":178,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"reported"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/19420862.2021.2014296","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T01:05:03Z","timestamp":1642208703000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":332,"title":["Antibodies to watch in 2022"],"prefix":"10.1080","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-2195","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Kaplon","sequence":"first","affiliation":[{"name":"Translational Medicine Department, Institut de Recherches Internationales Servier, Suresnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2736-9268","authenticated-orcid":false,"given":"Alicia","family":"Chenoweth","sequence":"additional","affiliation":[{"name":"St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-5957","authenticated-orcid":false,"given":"Silvia","family":"Crescioli","sequence":"additional","affiliation":[{"name":"St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-1951","authenticated-orcid":false,"given":"Janice M.","family":"Reichert","sequence":"additional","affiliation":[{"name":"The Antibody Society, Inc, Framingham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.1.10677"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00079-7"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2021.06.0162"},{"key":"e_1_3_5_5_1","unstructured":"Centers for Disease Control and Prevention. SARS-CoV-2Variant classifications and definitions. [Updated 2021 Oct 4 [accessed 2021 Nov 1]. www.cdc.gov\/coronavirus\/2019-ncov\/variants\/variant-info.html."},{"key":"e_1_3_5_6_1","unstructured":"U.S. Food and Drug Administration. Emergency use authorization. [Updated 2021 Oct 29 accessed 2021 Nov 1]. www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization."},{"key":"e_1_3_5_7_1","unstructured":"European Medicines Agency. COVID-19 treatments. [accessed 2021 Nov 1]. www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-treatments."},{"key":"e_1_3_5_8_1","unstructured":"European Medicines Agency. COVID-19 treatments: article 5 (3) reviews. [accessed 2021 Nov 1]. www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/treatments-covid-19\/covid-19-treatments-article-53-reviews."},{"key":"e_1_3_5_9_1","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. 2021 Feb 9 press release [accessed 2021 Nov 1]. www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0."},{"key":"e_1_3_5_10_1","unstructured":"U.S. Food and Drug Administration. FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. 2021 Sept 16 press release [accessed 2021 Nov 1]. www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis."},{"key":"e_1_3_5_11_1","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. 2021 Apr 16. press release [accessed 2021 Nov 1]. www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab."},{"key":"e_1_3_5_12_1","unstructured":"European Medicines Agency. EMA\/177113\/2021 assessment report: procedure under article 5 (3)of regulation (EC) No 726\/2004 Eli Lilly and company limited use of bamlanivimab and etesevimab for the treatment of COVID-19. 2021 Mar 16 [accessed 2021 Nov 1]. www.ema.europa.eu\/en\/documents\/referral\/eli-lilly-company-limited-antibody-combination-bamlanivimab\/etesevimab-covid19-article-53-procedure-assessment-report_en.pdf."},{"key":"e_1_3_5_13_1","unstructured":"Eli Lilly and Company Limited. Withdrawal of rolling review for bamlanivimab (EMEA\/H\/C\/005836\/0000) and etesevimab. 2021 Oct 29 letter [accessed 2021 Nov 3]. www.ema.europa.eu\/en\/documents\/withdrawal-letter\/withdrawal-letter-bamlanivimab-etesevimab_.pdf."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102685"},{"key":"e_1_3_5_15_1","unstructured":"Eli Lilly and Company. Lilly\u2019s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial reducing risk by up to 80 percent for residents. 2021 Jan 20 press release [accessed 2021 Nov 3]. investor.lilly.com\/news-releases\/news-release-details\/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-prevented."},{"key":"e_1_3_5_16_1","unstructured":"U.S. Food and Drug Administration. Emergency use authorization (EUA) for bamlanivimab 700 mg and etesevimab 1 400 mg. center for drug evaluation and research (CDER) review. [accessed 2020 Nov 1]. www.fda.gov\/media\/152756\/download."},{"key":"e_1_3_5_17_1","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional monoclonal antibody for treatment of COVID-19. 2021 May 26 press release [accessed 2021 Nov 1]. www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19."},{"key":"e_1_3_5_18_1","unstructured":"Therapeutic Goods Administration. Australian public assessment report for sotrovimab proprietary product name: xevudy; sponsor: glaxoSmithKline Australia pty ltd. [accessed 2021 Nov 1]. www.tga.gov.au\/sites\/default\/files\/auspar-sotrovimab-210820.pdf."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20602-5"},{"key":"e_1_3_5_21_1","unstructured":"Celltrion Group. Celltrion submits marketing authorisation application to the European medicines agency for regdanvimab (CT-P59). 2021 Oct 5 press release [accessed 2021 Nov 3]. www.celltrionhealthcare.com\/en-us\/board\/newsdetail?modify_key=529&pagenumber=1&keyword=&keyword_type=."},{"key":"e_1_3_5_22_1","unstructured":"European Medicines Agency. EMA\/192245\/2021 assessment report: procedure under article 5 (3)of regulation (EC) no 726\/2004 celltrion use of regdanvimab for the treatment of COVID-19. 2021 Mar 25 [accessed 2021 Nov 1]. www.ema.europa.eu\/en\/documents\/referral\/regdanvimab-treatment-covid-19-celltrion-covid-19-article-53-procedure-assessment-report_en.pdf."},{"key":"e_1_3_5_23_1","unstructured":"U.S. Food and Drug Administration. Emergency use authorization (EUA) for casirivimab and imdevimab. [accessed 2021 Nov 1]. www.fda.gov\/media\/151863\/download."},{"key":"e_1_3_5_24_1","unstructured":"Regeneron Pharmaceuticals Inc. New REGEN-COV\u2122 (casirivimab and imdevimab) data show supportive results in patients hospitalized with COVID-19. 2021 Sep 30 press release [accessed 2021 Nov 3]. investor.regeneron.com\/news-releases\/news-release-details\/new-regen-covtm-casirivimab-and-imdevimab-data-show-supportive."},{"key":"e_1_3_5_25_1","unstructured":"European Medicines Agency. EMA receives application for marketing authorisation for ronapreve (casirivimab\/imdevimab) for treatment and prevention of COVID-19. 2021 Oct 11 press release [accessed 2021 Nov]. www.ema.europa.eu\/en\/news\/ema-receives-application-marketing-authorisation-ronapreve-casirivimab-imdevimab-treatment."},{"key":"e_1_3_5_26_1","unstructured":"Therapeutic Goods Administration. Australian product information: ronapreve\u00ae (casirivimab and imdevimab). [accessed 2021 Nov 1]. www.tga.gov.au\/sites\/default\/files\/ronapreve-pi.pdf."},{"key":"e_1_3_5_27_1","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes drug for treatment of COVID-19. 2021 June 24 press release [accessed 2021 Nov 3]. www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19."},{"key":"e_1_3_5_28_1","unstructured":"U.S. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Actemra\u00ae (tocilizumab). [accessed 2021 Nov 3]. www.fda.gov\/media\/150321\/download."},{"key":"e_1_3_5_29_1","unstructured":"AstraZeneca. Year to date and Q3 2021 results. 2021 Nov 12 press release [accessed 2021 Nov 12]. www.astrazeneca.com\/content\/dam\/az\/PDF\/2021\/q3\/Year-to-date_and_Q3_2021_results_announcement.pdf."},{"key":"e_1_3_5_30_1","unstructured":"AstraZeneca. AZD7442 PROVENT phase III prophylaxis trial met primary endpoint in preventing COVID-19. 2021 Aug 20 press release [accessed 2021 Nov 3]. www.astrazeneca.com\/media-centre\/press-releases\/2021\/azd7442-prophylaxis-trial-met-primary-endpoint.html."},{"key":"e_1_3_5_31_1","unstructured":"AstraZeneca. AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE phase III outpatient treatment trial. 2021 Oct 11 press release [accessed 2021 Nov 3]. www.astrazeneca.com\/media-centre\/press-releases\/2021\/azd7442-phiii-trial-positive-in-covid-outpatients.html."},{"key":"e_1_3_5_32_1","unstructured":"Brii Biosciences. Corporate presentation. 2021 Oct [accessed 2021 Nov 3]. www.briibio.com\/upload\/BriiBio-Corporate-Presentation.pdf."},{"key":"e_1_3_5_33_1","unstructured":"Brii Biosciences. Brii bio initiates submission of emergency use authorization filing to U.S. FDA for BRII-196\/BRII-198 its monoclonal antibody combination therapy for non-hospitalized COVID-19 patients at high risk of clinical progression to severe disease. 2021 Oct 9 press release [accessed Nov 3 2021]. www.briibio.com\/news-detial.php?id=370#news."},{"key":"e_1_3_5_34_1","unstructured":"National Institutes of Health. NIH-Sponsored ACTIV-3. Clinical trial closes enrollment into two sub-studies. 2021 Mar 4 press release [accessed Nov 3 2021]. www.nih.gov\/news-events\/news-releases\/nih-sponsored-activ-3-clinical-trial-closes-enrollment-into-two-sub-studies."},{"key":"e_1_3_5_35_1","unstructured":"Adagio Therapeutics Inc. Adagio Therapeutics provides update for ADG20 COVID-19 antibody program and reports third quarter 2021 financial results. 2021 Nov 15 [accessed 2021 Nov 15]. investors.adagiotx.com\/news-releases\/news-release-details\/adagio-therapeutics-provides-update-adg20-covid-19-antibody."},{"key":"e_1_3_5_36_1","unstructured":"Humanigen Inc. Humanigen submits all planned modules for potential conditional marketing authorization from the UK\u2019s MHRA. 2021 Oct 1 press release [accessed 2021 Nov 3]. s28.q4cdn.com\/539885110\/files\/doc_news\/Humanigen-Submits-All-Planned-Modules-for-Potential-Conditional-Marketing-Authorization-from-the-UKs-MHRA-2021.pdf."},{"key":"e_1_3_5_37_1","unstructured":"Humanigen Inc. Humanigen presentation. 2021 Sept [accessed 2021 Nov 3]. s28.q4cdn.com\/539885110\/files\/doc_presentations\/2021\/September\/HGEN-Corporate-Deck-presented-at-Oppenheimer-Fall-Summit-Sep.-22-2021.pdf."},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.01.21256470"},{"key":"e_1_3_5_39_1","unstructured":"U.S. Food and Drug Administration. BLA 761181 approval letter. 2021 Feb 11 [accessed 2021 Nov 1]. www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/761181Orig1s000ltr.pdf."},{"key":"e_1_3_5_40_1","unstructured":"European Medicines Agency. Evkeeza assessment report EMA\/250315\/2021. [accessed 2021 Nov 1]. www.ema.europa.eu\/en\/documents\/assessment-report\/evkeeza-h-c-5449-0000-epar-assessment-report_en.pdf."},{"key":"e_1_3_5_41_1","unstructured":"European Medicines Agency. Jemperli assessment report EMA\/176464\/2021. [accessed 2021 Nov 1]. www.ema.europa.eu\/en\/documents\/assessment-report\/jemperli-epar-public-assessment-report_en.pdf."},{"key":"e_1_3_5_42_1","unstructured":"U.S. Food and Drug Administration. BLA 761174 approval letter. 2021Apr 22 [accessed 2021 Nov 1]. www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/761174Orig1s000ltr.pdf."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1954136"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fopow.2021.08.015"},{"key":"e_1_3_5_46_1","unstructured":"U.S. Food and Drug Administration. BLA 761196 approval letter. 2021 Apr 23 [accessed 2021 Nov 1]. www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/761196Orig1s000ltr.pdf."},{"key":"e_1_3_5_47_1","unstructured":"U.S. Food and Drug Administration. NDA\/BLA multi-disciplinary review and evaluation: BLA 761210; RYBREVANT amivantamab-vmjw. [accessed 2021 Nov 1]. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761210Orig1s000MultidisciplineR.pdf."},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100641"},{"key":"e_1_3_5_49_1","unstructured":"U.S. Food and Drug Administration. ADUHELM\u2122 application number 761178Orig1s000: clinical pharmacology and biopharmaceutics review(s). www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761178Orig1s000ClinPharm_Redacted.pdf."},{"key":"e_1_3_5_50_1","unstructured":"U.S. Food and Drug Administration. BLA 761178 approval letter. 2021 Jun 7 [accessed 2021 Nov 4]. www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/761178Orig1s000ltr.pdf."},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1664365"},{"key":"e_1_3_5_52_1","unstructured":"European Medicines Agency. EMA\/266138\/2021 assessment report: adtralza. 2021 Apr 22 [accessed 2021 Nov 4]. www.ema.europa.eu\/en\/documents\/assessment-report\/adtralza-h-c-5255-0000-epar-assessment-report_en.pdf."},{"key":"e_1_3_5_53_1","unstructured":"LEO Pharma A\/S. Update on U.S. FDA review of LEO pharma\u2019s biologics license application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis. 2021 Apr 29 press release [accessed 2021 Nov 4]. www.leo-pharma.us\/Files\/Billeder\/leo-us\/Press%20Release_FDA_Review_tralokinumab.pdf."},{"key":"e_1_3_5_54_1","unstructured":"AstraZeneca. Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus. 2021 Aug 2 press release [accessed 2021 Nov 4]. www.astrazeneca.com\/media-centre\/press-releases\/2021\/saphnelo-approved-in-the-us-for-sle.html."},{"key":"e_1_3_5_55_1","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information: SAPHNELO (anifrolumab-fnia) injection for intravenous use. [Revised 2021 Jul 21 accessed 2021 Nov 4]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761123s000lbl.pdf."},{"key":"e_1_3_5_56_1","unstructured":"European Medicines Agency. EMA\/393532\/2021 assessment report: bimzelx. 2021 Jun 24 [accessed 2021 Nov 4]. www.ema.europa.eu\/en\/documents\/assessment-report\/bimzelx-epar-public-assessment-report_en.pdf."},{"key":"e_1_3_5_57_1","unstructured":"UCB. Update on U.S. FDA review of biologics license application (BLA) for bimekizumab. 2021 Oct 16 press release [accessed 2021 Nov 4]. www.ucb.com\/stories-media\/Press-Releases\/article\/Update-on-U-S-FDA-Review-of-Biologics-License-Application-BLA-for-bimekizumab."},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"e_1_3_5_62_1","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information TIVDAKTM (tisotumab vedotin-tftv) for injection for intravenous use. Revised 2021 Sept [accessed 2021 Nov 4]. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761208s000lbl.pdf."},{"key":"e_1_3_5_63_1","unstructured":"JCR Pharmaceuticals Co. Ltd. JCR pharmaceuticals announces approval of IZCARGO\u00ae (pabinafusp alfa) for treatment of MPS II (hunter syndrome) in Japan. 2021 Mar 23 press release [accessed 2021 Nov 4]. ssl4.eir-parts.net\/doc\/4552\/tdnet\/1946438\/00.pdf."},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.039"},{"key":"e_1_3_5_65_1","unstructured":"Seagen Inc. Seagen and remeGen announce exclusive worldwide license and co-development agreement for disitamab vedotin. 2021 Aug 9 press release [accessed Nov 4 2021]. investor.seagen.com\/press-releases\/news-details\/2021\/Seagen-and-RemeGen-Announce-Exclusive-Worldwide-License-and-Co-Development-Agreement-for-Disitamab-Vedotin\/default.aspx."},{"key":"e_1_3_5_66_1","unstructured":"RemeGen Co. Ltd. China ushered in the first self-developed ADC new drug vidicuzumab for gastric cancer indications approved for marketing. 2021 June 10 press release [accessed 2021 Nov 4]. www.remegen.cn\/Invest2.aspx?ID=342."},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4560"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01444-0"},{"key":"e_1_3_5_69_1","unstructured":"Akeso Inc. Penpulimab monoclonal antibody (PD-1) obtains marketing approval in China. 2021 Aug 5 press release [accessed 2021 Nov 6]. www.akesobio.com\/en\/media\/akeso-news\/2021-8-5\/."},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.07.021"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1733"},{"key":"e_1_3_5_72_1","unstructured":"Akeso Inc. New drug application for cadonilimab (PD-1\/CTLA-4 bi-specific antibody) for the treatment of relapsed or metastatic cervical cancer accepted by NMPA. 2021 Sept 24 press release [accessed 2021 Nov 6]. www.akesobio.com\/en\/media\/akeso-news\/210924\/."},{"key":"e_1_3_5_73_1","unstructured":"Akeso Inc. 2020 annual results presentation. 2021 Mar [accessed 2021 Nov 5]. www.akesobio.com\/media\/1404\/akesoplus2020plusarpluspresentation_ve-website.pdf."},{"key":"e_1_3_5_74_1","unstructured":"Genor Biopharma Co. Inc. Untitled. 2020 Aug 5 press release [accessed 2021 Nov 4]. www.genorbio.com\/en\/media\/corporate-news\/nmpa-granted-priority-review-status-to-geptanolimab\/."},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01033-1"},{"key":"e_1_3_5_76_1","unstructured":"Shanghai Henlius Biotech Inc. The NDA of the novel anti-PD-1 serplulimab of henlius accepted by NMPA and proposed to be granted priority review. 2021 Apr 22 press release [accessed 2021 Nov 5]. www.henlius.com\/en\/NewsDetails-3031-26.html."},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2566"},{"key":"e_1_3_5_78_1","unstructured":"Shanghai Henlius Biotech Inc. The NDA of henlius novel anti-PD-1 mab serplulimab for first-line treatment of sqNSCLC accepted by China\u2019s NMPA phase 3 MRCT met its primary endpoint. 2021 Sept 17 press release [accessed 2021 Nov 5]. www.prnewswire.com\/news-releases\/the-nda-of-henlius-novel-anti-pd-1-mab-serplulimab-for-first-line-treatment-of-sqnsclc-accepted-by-chinas-nmpa-phase-3-mrct-met-its-primary-endpoint-301379340.html."},{"key":"e_1_3_5_79_1","unstructured":"Alphamab Oncology. Alphamab Oncology reports full year 2020 financial results and business highlights. 2021 Mar 23 press release [accessed 2021 Nov 5]. www.alphamabonc.com\/en\/html\/news\/2217.html."},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5504"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS11581"},{"key":"e_1_3_5_82_1","unstructured":"CStone Pharmaceuticals. CStone announces China\u2019s NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC. 2021 Sept 2 press release [accessed 2021 Nov 5]. www.cstonepharma.com\/en\/html\/news\/2645.html."},{"key":"e_1_3_5_83_1","unstructured":"CStone Pharmaceuticals. CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC. 2021 Sept 14 press release [accessed 2021 Nov 5]. www.cstonepharma.com\/en\/html\/news\/2652.html."},{"key":"e_1_3_5_84_1","unstructured":"CStone Pharmaceuticals. CStone will present registrational clinical study data of sugemalimab in patients with stage III non-small cell lung cancer in an oral presentation at ESMO congress. 2021 Sept 17 press release [accessed 2021 Nov 5]. www.cstonepharma.com\/en\/html\/news\/2656.html."},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2016.02.07"},{"key":"e_1_3_5_86_1","unstructured":"Sorrento Therapeutics Inc. Sorrento\u2019s license partner Lee\u2019s pharmaceutical announces NDA filing acceptance by NMPA for anti-PD-L1 antibody socazolimab for treatment of recurrent or metastatic cervical cancer. 2021 Nov 1 press release [accessed 2021 Nov 2]. investors.sorrentotherapeutics.com\/news-releases\/news-release-details\/sorrentos-license-partner-lees-pharmaceutical-announces-nda."},{"key":"e_1_3_5_87_1","unstructured":"Taisho Pharmaceutical Co. Ltd. Notification of application for approval to manufacture and market anti-tnf\u03b1 multivalent NANOBODY\u00ae compound (ozoralizumab) in Japan. 2021 Mar 22 press release [accessed 2021 Sept 13]. www.taisho.co.jp\/global\/news\/2021\/20210322000753.html."},{"key":"e_1_3_5_88_1","unstructured":"I-Mab. I-Mab advances late-stage development of its differentiated CD38 antibody felzartamab (TJ202) in China. 2021 Oct 13 press release [accessed 2021 Nov 5]. www.i-mabbiopharma.com\/en\/article-700.aspx."},{"key":"e_1_3_5_89_1","unstructured":"Genentech. FDA accepts application for genentech\u2019s faricimab for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). 2021 July 28 press release [accessed 2021 Nov 5]. www.gene.com\/media\/press-releases\/14923\/2021-07-28\/fda-accepts-application-for-genentechs-f."},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027760"},{"key":"e_1_3_5_91_1","unstructured":"Sanofi. Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER. 2021 Oct 28 press release [accessed 2021 Nov 6]. www.sanofi.com\/-\/media\/Project\/One-Sanofi-Web\/Websites\/Global\/Sanofi-COM\/Home\/media-room\/press-releases\/2021\/Press_Release_Q3_2021_EN.pdf."},{"key":"e_1_3_5_92_1","unstructured":"Sanofi. New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational c1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD a serious and chronic autoimmune hemolytic anemia. 2021 June 11 press release [accessed 2021 Nov 6]. www.sanofi.com\/en\/media-room\/press-releases\/2021\/2021-06-11-09-00-00-2245658."},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070971"},{"key":"e_1_3_5_94_1","unstructured":"Immunocore Holdings Plc. Immunocore announces that U.S. Food and Drug Administration and European Medicines Agency accept biologics license application and marketing authorization application for tebentafusp in metastatic uveal melanoma. 2021 Aug 24 press release [accessed 2021 Nov 5]. ir.immunocore.com\/news-releases\/news-release-details\/immunocore-announces-us-food-and-drug-administration-and."},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-CT002"},{"key":"e_1_3_5_96_1","unstructured":"Bristol Myers Squibb. U.S. Food and drug administration accepts for priority review Bristol Myers Squibb\u2019s application for LAG-3-blocking antibody relatlimab and nivolumab fixed-dose combination as treatment for patients with unresectable or metastatic melanoma. 2021 Sept 20 press release [accessed 2021 Nov 5]. news.bms.com\/news\/corporate-financial\/2021\/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-LAG-3-Blocking-Antibody-Relatlimab-and-Nivolumab-Fixed-Dose-Combination-as-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma\/default.aspx."},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9503"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.594558"},{"key":"e_1_3_5_99_1","unstructured":"Innovent Biologics Inc. U.S. FDA accepts regulatory submission for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer. 2021 May 18 press release [accessed 2021 Nov 5]. www.prnewswire.com\/news-releases\/us-fda-accepts-regulatory-submission-for-sintilimab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-people-with-nonsquamous-non-small-cell-lung-cancer-301293152.html."},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014"},{"key":"e_1_3_5_101_1","unstructured":"Innovent Biologics Inc. Innovent announces sintilimab in combination with chemotherapy meets the primary endpoint of overall survival in the phase 3 ORIENT-16 study for the first-line treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. 2021 Aug 15 press release [accessed 2021 Nov 5]. www.prnewswire.com\/news-releases\/innovent-announces-sintilimab-in-combination-with-chemotherapy-meets-the-primary-endpoint-of-overall-survival-in-the-phase-3-orient-16-study-for-the-first-line-treatment-of-advanced-or-metastatic-gastric-or-gastroesophageal-juncti-301355470.html."},{"key":"e_1_3_5_102_1","unstructured":"TG Therapeutics Inc. TG therapeutics announces FDA acceptance of biologics license application for ublituximab in combination with UKONIQ\u00ae (umbralisib) as a treatment for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. 2021 May 25 press release [accessed 2021 Nov 5]. ir.tgtherapeutics.com\/news-releases\/news-release-details\/tg-therapeutics-announces-fda-acceptance-biologics-license."},{"key":"e_1_3_5_103_1","unstructured":"TG Therapeutics Inc. TG therapeutics submits biologics license application to the U.S. Food and Drug Administration for ublituximab as a treatment for patients with relapsing forms of multiple sclerosis. 2021 Sept 30 press release [accessed 2021 Nov 5]. ir.tgtherapeutics.com\/news-releases\/news-release-details\/tg-therapeutics-submits-biologics-license-application-us-food."},{"key":"e_1_3_5_104_1","unstructured":"Steinman L Fox E Hartung H-P Enrique Alvarez E Qian P Wray S Robertson D Huang D Selmaj K Wynn D et al. Phase 3 results of the ULTIMATE I & II global studies: ublituximab versus teriflunomide in relapsing multiple sclerosis. European Committee for Treatment and Research in Multiple Sclerosis; 2021 Oct 13-15 Virtual presentation [accessed 2021 Nov. www.tgtherapeutics.com\/wp-content\/uploads\/2021\/10\/Steinman-ORAL-ECTRIMS-2021-PH3-ULTIMATE-I-II-10.13.21.pdf."},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"},{"key":"e_1_3_5_106_1","unstructured":"Amgen. New tezepelumab data show 86% reduction in exacerbations in patients with severe asthma and comorbid nasal polyps. 2021 Sept 5 press release [accessed 2021 Nov 6]. www.amgen.com\/newsroom\/press-releases\/2021\/09\/new-tezepelumab-data-show-86-reduction-in-exacerbations-in-patients-with-severe-asthma-and-comorbid-nasal-polyps."},{"key":"e_1_3_5_107_1","unstructured":"Akeso Inc. Akeso penpulimab monoclonal antibody (PD-1) submitted BLA in the United States. 2021 May 24 press release [accessed 2021 Nov 4]. www.akesobio.com\/en\/media\/akeso-news\/21-5-24\/."},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0804"},{"key":"e_1_3_5_109_1","unstructured":"BeiGene Ltd. BeiGene announces U.S. FDA acceptance of biologics license application for tislelizumab in esophageal squamous cell carcinoma. 2021 Sept 13 press release [accessed 2021 Sept 13]. ir.beigene.com\/news-details\/?id=5c97c078-8ee7-4a4e-aba3-19d5a9dac715."},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4012"},{"key":"e_1_3_5_111_1","unstructured":"BeiGene Ltd. China national medical products administration approves beigene\u2019s tislelizumab for patients with classical hodgkin\u2019s lymphoma who have received at least two prior therapies. 2019 Dec 27 press release [accessed 2021 Nov 6]. ir.beigene.com\/news-details\/?id=e524da7d-6573-4abb-8c9a-dc5672ea87aa."},{"key":"e_1_3_5_112_1","unstructured":"BeiGene Ltd. China national medical products administration approves beigene\u2019s tislelizumab for patients with previously treated locally advanced or metastatic urothelial carcinoma. 2020 Apr 10 press release [accessed 2021 Nov 6]. ir.beigene.com\/news-details\/?id=9d7cfa84-81fd-44e1-b8dc-f5d82068095a."},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14681"},{"key":"e_1_3_5_114_1","unstructured":"BeiGene Ltd. China national medical products administration approves tislelizumab in combination with chemotherapy in first-line advanced squamous non-small cell lung cancer. 2021 Jan 13 press release [accessed 2021 Nov 6]. ir.beigene.com\/news-details\/?id=bafd0e50-64fe-4313-9f63-a58be0fc2c54."},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366"},{"key":"e_1_3_5_116_1","unstructured":"BeiGene Ltd. China NMPA approves tislelizumab in non-small cell lung cancer and hepatocellular carcinoma. 2021 June 23 press release [accessed 2021 Nov 6]. ir.beigene.com\/news-details\/?id=06abb5cf-b5fa-405e-9d3b-e800e1106b99."},{"key":"e_1_3_5_117_1","unstructured":"Eisai Co. Ltd. Biogen Inc. Eisai initiates rolling submission to the U.S. FDA for biologics license application of lecanemab (BAN2401) for early alzheimer\u2019s disease under the accelerated approval pathway. 2021 Sept 28 press release [accessed 2021 Nov 6]. www.eisai.com\/news\/2021\/pdf\/enews202177pdf.pdf."},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"e_1_3_5_119_1","unstructured":"Coherus BioSciences Inc. Shanghai Junshi Biosciences Co. Ltd. Coherus and Junshi Biosciences announce FDA acceptance of BLA filing for toripalimab for treatment of nasopharyngeal carcinoma. 2021 Nov 1 press release [accessed 2021 Nov 6]. investors.coherus.com\/news-releases\/news-release-details\/coherus-and-junshi-biosciences-announce-fda-acceptance-bla."},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02712"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01444-0"},{"key":"e_1_3_5_122_1","unstructured":"Coherus BioSciences Inc. Coherus and Junshi Biosciences announce positive interim results of CHOICE-01 a phase 3 clinical trial evaluating toripalimab in combination with chemotherapy as first-line treatment for non-small cell lung cancer. 2021 Aug 18 press release [accessed 2021 Nov 6]. investors.coherus.com\/news-releases\/news-release-details\/coherus-and-junshi-biosciences-announce-positive-interim-results\/."},{"key":"e_1_3_5_123_1","unstructured":"ElsaLys Biotech SA. While ElsaLys continues to work on the filing of marketing approval in Europe and the U.S. for inolimomab the company confirms the renew of its cohort ATU in France and compassionate use programs submissions in several other countries. 2021 Apr 14 press release [accessed 2021 Nov 6]. www.elsalysbiotech.com\/node\/118."},{"key":"e_1_3_5_124_1","unstructured":"Y-mAbs Therapeutics Inc. Y-mAbs submits omburtamab marketing authorization application to the European medicines agency. 2021 Apr 27 press release [accessed 2021 Nov 6]. ir.ymabs.com\/news-releases\/news-release-details\/y-mabs-submits-omburtamab-marketing-authorization-application."},{"key":"e_1_3_5_125_1","unstructured":"Y-mAbs Therapeutics Inc. Y-mAbs announces third quarter financial results and recent corporate developments. 2021 Nov 4 press release [accessed 2021 Nov 5]. ir.ymabs.com\/news-releases\/news-release-details\/y-mabs-announces-third-quarter-financial-results-and-recent."},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22169048"},{"key":"e_1_3_5_127_1","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim announces European Medicines Agency\u2019s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis. 2021 Oct 29 press release [accessed 2021 Nov 6]. www.boehringer-ingelheim.com\/press-release\/ema-filing-acceptance-and-validation-spesolimab."},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043666"},{"key":"e_1_3_5_129_1","unstructured":"U.S. Food and Drug Administration. FDA briefing document endocrinologic and metabolic drugs advisory committee meeting: teplizumab BLA 761183. 2021 May 27 [accessed 2021 Nov 5]. www.fda.gov\/media\/149388\/download."},{"key":"e_1_3_5_130_1","unstructured":"Provention Bio Inc. Provention bio receives complete response letter (CRL) to biologics license application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. 2021 July 6 press release [accessed 2021 Nov 6]. investors.proventionbio.com\/2021-07-06-Provention-Bio-Receives-Complete-Response-Letter-CRL-to-Biologics-License-Application-BLA-for-Teplizumab-for-the-Delay-of-Clinical-Type-1-Diabetes-T1D-in-At-risk-Individuals."},{"key":"e_1_3_5_131_1","unstructured":"U.S. Food and Drug Administration. FDA briefing document oncologic drugs advisory committee meeting: retifanlimab-dlwr infusion BLA 761209. 2021 June 24 [accessed 2021 Nov 5]. www.fda.gov\/media\/150251\/download."},{"key":"e_1_3_5_132_1","unstructured":"Incyte Corporation. Incyte announces outcome of FDA Oncologic Drugs Advisory Committee (ODAC) meeting reviewing retifanlimab as a treatment for patients with squamous cell carcinoma of the anal canal (SCAC). 2021 June 24 press release [accessed 2021 Nov 6]. investor.incyte.com\/press-releases\/press-releases\/2021\/Incyte-Announces-Outcome-of-FDA-Oncologic-Drugs-Advisory-Committee-ODAC-Meeting-Reviewing-Retifanlimab-as-a-Treatment-for-Patients-with-Squamous-Cell-Carcinoma-of-the-Anal-Canal-SCAC\/default.aspx."},{"key":"e_1_3_5_133_1","unstructured":"Incyte Corporation. Incyte provides regulatory update on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the anal canal (SCAC). 2021 July 23 press release [accessed 2021 Nov 6]. investor.incyte.com\/press-releases\/press-releases\/2021\/Incyte-Provides-Regulatory-Update-on-Retifanlimab-for-the-Treatment-of-Certain-Patients-with-Squamous-Cell-Carcinoma-of-the-Anal-Canal-SCAC\/default.aspx."},{"key":"e_1_3_5_134_1","unstructured":"Sesen Bio Inc. Business update call. 2021 2021 Aug 16 [accessed 2021 Nov 6]. ir.sesenbio.com\/static-files\/cb6d46da-104c-4721-bfc3-f38c18711b71."},{"key":"e_1_3_5_135_1","unstructured":"Sesen Bio Inc. United States securities and exchange commission form 8-K. 2021 Aug 20 [accessed 2021 Nov 6]. ir.sesenbio.com\/static-files\/4b10acb3-3750-4995-b9ce-48a820549f0b."},{"key":"e_1_3_5_136_1","unstructured":"Omeros Corporation. Omeros provides regulatory update on biologics license application for narsoplimab in the treatment of HSCT-TMA. 2021 Oct 1 press release [accessed 2021 Nov 5]. investor.omeros.com\/news-releases\/news-release-details\/omeros-provides-regulatory-update-biologics-license-application."},{"key":"e_1_3_5_137_1","unstructured":"Perales M-A Cairo MS Duarte RF Giralt S Ho -VT-V Laurence J Leung N Penack O Rambaldi A Scordo M et al. Narsoplimab (OMS721) treatment contributes to improvements in organ function in adult patients with high-risk transplant-associated thrombotic microangiopathy. European Hematology Association; 2021 June 11 [accessed 2021 Nov 5]. investor.omeros.com\/static-files\/bcb7c499-95e8-4a21-a4f9-4fe64df750d8."},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1860476"},{"key":"e_1_3_5_140_1","unstructured":"PhaseBio Pharmaceuticals Inc. PhaseBio announces interim results from pivotal REVERSE-IT phase 3 trial of bentracimab for the reversal of antiplatelet effects of ticagrelor in patients requiring urgent surgery or experiencing uncontrolled major or life-threatening bleeding. 2021 Nov 15 press release [accessed 2021 Nov 16]. investors.phasebio.com\/news-releases\/news-release-details\/phasebio-announces-interim-results-pivotal-reverse-it-phase-3."},{"key":"e_1_3_5_141_1","unstructured":"Chugai Pharmaceuticals. Chugai\u2019s strategy for drug discovery research. 2019 Dec 9 presentation [accessed 2021 Nov 6]. www.chugai-pharm.co.jp\/cont_file_dl.php?f=FILE_1_85.pdf&src=[%0] [%1]&rep=139 85."},{"key":"e_1_3_5_142_1","unstructured":"Roche. Roche pharma day 2021. 2021 Sept 14 presentation [accessed 2021 Nov 6]. www.roche.com\/dam\/jcr:178db2c0-31b1-4ad1-aaea-e7eff839bcf6\/en\/irp20210914.pdf."},{"key":"e_1_3_5_143_1","unstructured":"Roche. H2 2021 results. 2021 July 22 [accessed 2021 Nov 6]. www.roche.com\/dam\/jcr:a1437516-3f73-4112-a483-40c8b1c3836e\/en\/irp210722.pdf."},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2020.68"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01369-8"},{"key":"e_1_3_5_146_1","unstructured":"Novartis Pharmaceuticals Corporation. Q2 2021 results. Investor presentation; [accessed 2021 Nov 6]. www.novartis.com\/sites\/www.novartis.com\/files\/q2-2021-investor-presentation.pdf."},{"key":"e_1_3_5_147_1","unstructured":"AstraZeneca. Nirsevimab MELODY phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants. 2021 Apr 26 press release [accessed 2021 Oct 10]. www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2021\/nirsevimab-phase-iii-trial-met-primary-endpoint.html."},{"key":"e_1_3_5_148_1","unstructured":"AstraZeneca. Nirsevimab MEDLEY phase II\/III trial demonstrated favourable safety and tolerability profile in infants at high risk of RSV. 2021 June 28 press release [accessed 2021 Nov 5]. www.astrazeneca.com\/media-centre\/press-releases\/2021\/nirsevimab-phii-iii-trial-confirms-safety-profile.html."},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135839"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7520"},{"key":"e_1_3_5_151_1","unstructured":"Gilead Sciences Inc. Q3 21 financial results. 2021 Oct 28 [accessed 2021 Nov 6]. investors.gilead.com\/static-files\/cf9f2815-947e-4d97-adcc-7d50ee064075."},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fopow.2021.11.012"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5504"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1967714"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241091"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.005"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e16063"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.299"},{"key":"e_1_3_5_161_1","unstructured":"Zymeworks Inc. Zanidatamab phase 2 clinical trial demonstrates promising response rate and durability in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) annual congress. 2021 Sept 16 press release [accessed 2021 Nov 7]. ir.zymeworks.com\/news-releases\/news-release-details\/zanidatamab-phase-2-clinical-trial-demonstrates-promising."},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002736"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139192"},{"key":"e_1_3_5_164_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron corporate presentation. 2021 Nov [accessed 2021 Nov 7. investor.regeneron.com\/static-files\/fe9d17bb-38cc-4a2c-b96c-dbc4a79d072e."},{"key":"e_1_3_5_165_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8008"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136659"},{"key":"e_1_3_5_169_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136344"},{"key":"e_1_3_5_170_1","unstructured":"Novartis. Q3 2021 results: investor presentation. [accessed 2021 Nov 19. prod1.novartis.com\/sites\/novartis_com\/files\/q3-2021-investor-presentation.pdf."},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fopow.2021.11.012"},{"key":"e_1_3_5_172_1","unstructured":"Actinium Pharmaceuticals Inc. Actinium completes enrollment in the pivotal phase 3 SIERRA trial of Iomab-B. 2021 Sept 15 press release [accessed 2021 Nov 7]. ir.actiniumpharma.com\/press-releases\/detail\/401\/actinium-completes-enrollment-in-the-pivotal-phase-3-sierra."},{"key":"e_1_3_5_173_1","unstructured":"Actinium Pharmaceuticals Inc. Pivotal Phase 3 SIERRA trial data showing 100% bone marrow transplant engraftment in patients treated with Iomab-B presented at the 2021 virtual SNMMI conference. 2021 June 15 press release [accessed 2021 Nov 7]. ir.actiniumpharma.com\/press-releases\/detail\/398\/pivotal-phase-3-sierra-trial-data-showing-100-bone-marrow."},{"key":"e_1_3_5_174_1","unstructured":"Alphamab Oncology. Completion of patient enrollment in a phase III clinical trial of kn046 in combination with chemotherapy in the treatment of advanced unresectable or metastatic squamous NSCLC. 2021 Oct 15 press release [accessed 2021 Nov 6]. www1.hkexnews.hk\/listedco\/listconews\/sehk\/2021\/1015\/2021101501156.pdf."},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9060"},{"key":"e_1_3_5_176_1","unstructured":"Agenus. Agenus provides update on balstilimab development. 2021 Oct 22 press release [accessed 2021 Nov 7]. investor.agenusbio.com\/news-releases\/news-release-details\/agenus-provides-update-balstilimab-development."},{"key":"e_1_3_5_177_1","unstructured":"Pfizer Inc. Eli Lilly and Company. Joint FDA advisory committee votes on application for tanezumab for the treatment of osteoarthritis pain. 2021 Mar 25 press release [accessed 2021 Nov 7]. www.pfizer.com\/news\/press-release\/press-release-detail\/joint-fda-advisory-committee-votes-application-tanezumab."},{"key":"e_1_3_5_178_1","unstructured":"European Medicines Agency. EMA\/512898\/2021 EMEA\/H\/C\/005189\/0000: refusal of the marketing authorisation for raylumis (tanezumab). 2021 Sept 17 [accessed 2021 Nov 7]. www.ema.europa.eu\/en\/documents\/smop-initial\/questions-answers-refusal-marketing-authorisation-raylumis-tanezumab_en.pdf."},{"key":"e_1_3_5_179_1","unstructured":"Pfizer Inc. Pfizer reports third-quarter 2021 results. 2021 Nov 2 press release [accessed 2021 Nov 7] s21.q4cdn.com\/317678438\/files\/doc_financials\/2021\/q3\/Q3-2021-PFE-Earnings-Release.pdf."}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2021.2014296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T08:01:48Z","timestamp":1734336108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2021.2014296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":178,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/19420862.2021.2014296"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2021.2014296","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2014296"}}